IL292882B1 - Bruton's tyrosine kinase inhibitor dosage - Google Patents

Bruton's tyrosine kinase inhibitor dosage

Info

Publication number
IL292882B1
IL292882B1 IL292882A IL29288222A IL292882B1 IL 292882 B1 IL292882 B1 IL 292882B1 IL 292882 A IL292882 A IL 292882A IL 29288222 A IL29288222 A IL 29288222A IL 292882 B1 IL292882 B1 IL 292882B1
Authority
IL
Israel
Prior art keywords
bruton
dosing
tyrosine kinase
kinase inhibitor
inhibitor
Prior art date
Application number
IL292882A
Other languages
English (en)
Hebrew (he)
Other versions
IL292882A (en
Original Assignee
Loxo Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Loxo Oncology Inc filed Critical Loxo Oncology Inc
Publication of IL292882A publication Critical patent/IL292882A/en
Publication of IL292882B1 publication Critical patent/IL292882B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL292882A 2019-12-06 2020-12-03 Bruton's tyrosine kinase inhibitor dosage IL292882B1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962944674P 2019-12-06 2019-12-06
US202063077996P 2020-09-14 2020-09-14
US202063109698P 2020-11-04 2020-11-04
PCT/US2020/063089 WO2021113497A1 (en) 2019-12-06 2020-12-03 Dosing of a bruton's tyrosine kinase inhibitor

Publications (2)

Publication Number Publication Date
IL292882A IL292882A (en) 2022-07-01
IL292882B1 true IL292882B1 (en) 2026-05-01

Family

ID=73854977

Family Applications (1)

Application Number Title Priority Date Filing Date
IL292882A IL292882B1 (en) 2019-12-06 2020-12-03 Bruton's tyrosine kinase inhibitor dosage

Country Status (10)

Country Link
US (1) US12551463B2 (cg-RX-API-DMAC7.html)
EP (1) EP4069219A1 (cg-RX-API-DMAC7.html)
JP (3) JP7142173B2 (cg-RX-API-DMAC7.html)
KR (2) KR20220100992A (cg-RX-API-DMAC7.html)
CN (1) CN115175677A (cg-RX-API-DMAC7.html)
AU (2) AU2020397034B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022009716A2 (cg-RX-API-DMAC7.html)
IL (1) IL292882B1 (cg-RX-API-DMAC7.html)
MX (1) MX2022006631A (cg-RX-API-DMAC7.html)
WO (1) WO2021113497A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3108065C (en) 2018-07-31 2025-10-07 Loxo Oncology, Inc. SPRAY-DRIED DISPERSIONS, FORMULATIONS AND POLYMORPHIES OF (S)-5-AMINO-3-(4-((5-FLUORO-2-METHOXYBENZAMIDO)METHYL)PHENYL)(1,1,1-TRIFLUOROPROPANE-2-YL)-1H-PYRAZOLE-4-CARBOXAMIDE
KR20220100992A (ko) * 2019-12-06 2022-07-18 록쏘 온콜로지, 인코포레이티드 브루톤 티로신 키나제 억제제의 투여

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017103611A1 (en) * 2015-12-16 2017-06-22 Redx Pharma Plc Compounds useful as kinase inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2529621B1 (en) 2006-09-22 2016-10-05 Pharmacyclics LLC Inhibitors of bruton's tyrosine kinase
US20150291554A1 (en) 2012-11-02 2015-10-15 Pfizer Inc. Bruton's Tyrosine Kinase Inhibitors
US9717745B2 (en) 2015-03-19 2017-08-01 Zhejiang DTRM Biopharma Co. Ltd. Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases
WO2017132474A1 (en) 2016-01-30 2017-08-03 Newave Pharmaceutical Inc. Bcl-2 inhibitors
KR102376764B1 (ko) 2016-08-05 2022-03-18 더 리젠츠 오브 더 유니버시티 오브 미시건 Bcl-2 억제제로서의 n-(페닐설포닐)벤즈아미드 및 관련 화합물
CN110177788B (zh) 2017-01-07 2023-03-24 重庆复创医药研究有限公司 作为bcl-2选择性凋亡诱导剂的化合物
SI3612531T1 (sl) 2017-04-18 2022-11-30 Shanghai Fochon Pharmaceutical Co., Ltd. Sredstva, ki sprožajo apoptozo
JP2020528061A (ja) 2017-07-26 2020-09-17 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト BET阻害剤、Bcl−2阻害剤及び抗CD20抗体を用いた併用療法
IL316472A (en) 2018-01-10 2024-12-01 Recurium Ip Holdings Llc Benzamide compounds
CN112437772B (zh) 2018-04-29 2023-11-21 百济神州有限公司 Bcl-2抑制剂
CA3108065C (en) 2018-07-31 2025-10-07 Loxo Oncology, Inc. SPRAY-DRIED DISPERSIONS, FORMULATIONS AND POLYMORPHIES OF (S)-5-AMINO-3-(4-((5-FLUORO-2-METHOXYBENZAMIDO)METHYL)PHENYL)(1,1,1-TRIFLUOROPROPANE-2-YL)-1H-PYRAZOLE-4-CARBOXAMIDE
KR20220100992A (ko) * 2019-12-06 2022-07-18 록쏘 온콜로지, 인코포레이티드 브루톤 티로신 키나제 억제제의 투여

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017103611A1 (en) * 2015-12-16 2017-06-22 Redx Pharma Plc Compounds useful as kinase inhibitors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JERKEMAN, MATS, ET AL.,, IBRUTINIB, LENALIDOMIDE, AND RITUXIMAB IN RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA (PHILEMON): A MULTICENTRE, OPEN-LABEL, SINGLE-ARM, PHASE 2 TRIAL., 29 January 2018 (2018-01-29) *
NIEMANN, CARSTEN UTOFT, ET AL.,, VENETOCLAX AND IBRUTINIB FOR PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (R/R CLL)-15-MONTH SAFETY, RESPONSE AND MRD EVALUATION: THIRD INTERIM ANALYSIS FROM THE PHASE II VISION HO141 TRIAL., 13 November 2019 (2019-11-13) *

Also Published As

Publication number Publication date
EP4069219A1 (en) 2022-10-12
KR20230127372A (ko) 2023-08-31
CN115175677A (zh) 2022-10-11
AU2024201263B2 (en) 2025-05-01
JP2022177119A (ja) 2022-11-30
US12551463B2 (en) 2026-02-17
AU2020397034A1 (en) 2022-07-21
AU2024201263A1 (en) 2024-03-14
BR112022009716A2 (pt) 2022-08-09
IL292882A (en) 2022-07-01
JP2025098099A (ja) 2025-07-01
NZ788615A (en) 2024-10-25
CA3160417A1 (en) 2021-06-10
US20230041515A1 (en) 2023-02-09
MX2022006631A (es) 2022-09-07
AU2020397034B2 (en) 2023-12-07
JP7142173B2 (ja) 2022-09-26
JP7654604B2 (ja) 2025-04-01
KR20220100992A (ko) 2022-07-18
WO2021113497A1 (en) 2021-06-10
JP2022518974A (ja) 2022-03-17

Similar Documents

Publication Publication Date Title
ZA201907661B (en) Pharmaceutical formulations of a bruton's tyrosine kinase inhibitor
IL274716A (en) Synthesis of a proton tyrosine kinase inhibitor
IL261249A (en) Dosage preparations containing Bruton's tyrosine kinase inhibitor
IL285783A (en) Jak inhibitor compound and use thereof
ZA201903932B (en) Imidazopyrazine inhibitors of bruton's tyrosine kinase
IL250085A0 (en) New compounds of proton tyrosine kinase inhibitor
IL255831A (en) Inhibitors of bruton's tyrosine kinase
EP3273962A4 (en) Co-crystals of a bruton's tyrosine kinase inhibitor
IL287433A (en) Combination of anti-cd19 antibody and proton tyrosine kinase inhibitor and its uses
ZA201805439B (en) Bruton's tyrosine kinase inhibitors
ZA201903694B (en) Inhibitors of bruton's tyrosine kinase
ZA201906887B (en) Bruton's tyrosine kinase inhibitors
EP3273961A4 (en) Solvated forms of a bruton's tyrosine kinase inhibitor
PL3609886T3 (pl) Analogi benzoazepiny jako środki hamujące kinazę tyrozynową brutona
EP3969111A4 (en) Inhalable formulations for kinase inhibition
PL3972603T3 (pl) Sposoby leczenia zespołu sjögrena przy użyciu inhibitora kinazy tyrozynowej brutona
SI3972604T1 (sl) Brutonov zaviralec tirozin kinaze za zdravljenje kronične spontane urtikarije
IL264341A (en) Succinate forms and preparations of proton tyrosine kinase inhibitors
IL284916A (en) Cyclic molecules as Bruton's tyrosine kinase inhibitors
KR102668958B9 (ko) 브루톤 티로신 키나아제 억제제인 치환된 1-아미노-1h-이미다졸-5-카르복사미드
HK40072430A (en) Dosing of a bruton's tyrosine kinase inhibitor
EP3882241A4 (en) INHIBITOR OF BRUTON TYROSINE KINASE
MA55964A (fr) Agents inhibiteurs de la tyrosine kinase de bruton
EP4069689A4 (en) SUBSTITUTED IMIDAZOLECARBOXAMIDE AS BRUTON TYROSINKINASE INHIBITORS
HK40019173A (en) Inhibitors of bruton's tyrosine kinase